The FDA just handed AbbVie’s experimental cancer drug a double dose of regulatory love. A breakthrough therapy designation now covers Temab-A in both colorectal and lung cancer, AbbVie announced on Oct. 7.
That is a big headline for people running out of options. It is also not an approval, and that difference matters.
What the breakthrough therapy designation covers
The drug is telisotuzumab adizutecan, or Temab-A. It is an antibody-drug conjugate, which means an antibody that hunts down a target on cancer cells and delivers a chemotherapy-style payload. This one targets a protein called c-Met and carries a topoisomerase 1 inhibitor.
The first designation is for metastatic colorectal cancer. It applies to Temab-A combined with bevacizumab in adults whose disease is refractory. Those patients have already tried the standard lineup: fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF antibody and, if indicated, an anti-EGFR antibody. That is a long list of treatments already behind them.
The second is for non-small cell lung cancer. Here Temab-A would go solo, as a monotherapy. It targets adults with locally advanced or metastatic, EGFR wild-type, c-Met protein-expressing, non-squamous disease. Those patients have already received platinum-based chemotherapy and an anti-PD-(L)1 antibody.
Both designations rest mainly on a first-in-human study, according to AbbVie’s release. They are also the first such designations for Temab-A. In fact, AbbVie says its antibody-drug conjugate portfolio now holds four of them.
What the early colorectal numbers show
Some early data is already public. At the ESMO 2025 meeting, the combination cohort reported results in patients who were not selected by biomarker. At the 2.4 mg/kg dose, 30 patients had a median progression-free survival of 6.8 months, according to OncLive’s coverage.
At 2.0 mg/kg, 26 patients had a median of 5.6 months. Median overall survival in that group was 9.8 months. Those are small cohorts and early numbers, so treat them as a promising signal and not a verdict. That caution is exactly why the FDA breakthrough status is a starting line, not a finish.
Here’s the thing: designation is not approval
So what does a breakthrough designation actually do? It aims to speed up development and review of a drug. To qualify, early clinical evidence has to suggest a substantial improvement over existing therapies on an important endpoint.
It does not mean the drug works better than what is on the market. It also does not change what doctors prescribe today. Temab-A is still investigational, and no regulator has approved it anywhere. AbbVie has not announced a filing or approval date.
The EGFR wild-type detail in the lung cancer designation also matters. Patients with EGFR alterations follow a different treatment pathway, so this label targets a specific slice of lung cancer patients.
AbbVie is clearly excited. “These Breakthrough Therapy Designations reflect the growing clinical evidence supporting c-Met as a meaningful therapeutic target across multiple solid tumors,” said Eleni Lagkadinou, M.D., Ph.D., the company’s vice president of oncology early development.
AbbVie has been here before. Its earlier c-Met drug, telisotuzumab vedotin, earned a breakthrough designation back in January 2022 for a form of lung cancer. This time the company is betting on a next-generation version.
Regulators are moving fast on drug policy lately. For a related example, see how the peptide compounding sales plan is unfolding, or read about the push to phase out artificial food dyes. Meanwhile, health researchers are also tracking rising stroke rates in younger adults.
What happens next depends on larger trials. Those studies will show whether early promise holds up and whether Temab-A earns a place in clinics. For patients who have already burned through standard options, that answer cannot come soon enough.
